Gilad Glick, CEO, Itamar Medical

Gilad Glick,  is the CEO of Itamar Medical a publicly-traded medical device company (NASDAQ&TASE: ITMR) that develops and markets innovative diagnostic and therapy solutions for sleep apnea disorders and cardiovascular conditions. WatchPAT, the company's FDA-approved flagship product is used for diagnosing sleep apnea in the home environment.

Listen to this interview to learn:

1:00 Why did Gilad come back to Israel from a long relocation and a career overseas? 

5:10 Why did Gilad suffer from a culture shock when returning to Israel?

8:04  What Itamar Medical does and what drives the company.

10:21 How sleep and cardiology and inter-related. Why is sleep this important and to whom?

12:59 Where does Itamar Medical play in the new world of sleep and prevention of disease

15:14 How is sleep related to wellness and how is Itamar is becoming a key player in this market. 

15:35 Would Itamar consider selling its product directly to the end consumer as a complete package?

20:23  What Gilad thinks about an Israeli company public versus a US-based or European-based company being public? Is there a difference in the way that the local and international market sees an Israeli public company? 

25:24  What tips can Gilad offer to CEOs of publicly traded companies in Israel? 

27:16  Why did Itamar Medical acquire Spry?

30:20  What tips can Gilad offer for smaller companies looking to be acquired?

31:51  Examples of mistaken acquisitions in the ECG device market

33:42  How did the COVID pandemic affected Gilad, personally, and within the company.